Investing.com - Acumen Pharmaceuticals reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was in line with expectations.
Acumen Pharmaceuticals announced earnings per share of $-0.26 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.27 on revenue of $0.
Acumen Pharmaceuticals shares are down 20% from the beginning of the year, still down 53.52% from its 52 week high of $13.21 set on November 15, 2021.
Acumen Pharmaceuticals follows other major Healthcare sector earnings this month
Acumen Pharmaceuticals's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar